NEW YORK (GenomeWeb News) – Gen-Probe this week said that board chairman Hank Nordhoff plans to retire at the end of the year. The company said that current President and CEO Carl Hull will replace Nordhoff as board chairman. Nordhoff held the offices of president and CEO from 1994 to 2009, and he will continue to serve the firm as a consultant until the end of 2012.
Separately, the company also disclosed in a document filed with the US Securities and Exchange Commission that senior VP of research and development Eric Lai has resigned from his position. No reason was given and no replacement was named in the filing.
Agilent Technologies has appointed Ron Nersesian as executive vice president and chief operating officer role, effective immediately. Nersesian, who has been president of the firms' Electronic Measurement Group (EMG) since 2009, in the new role will have day-to-day responsibility for the company's three businesses, Chemical Analysis, Life Sciences, and EMG. Guy Séné, who has been vice president of the Microwave and Communications Division since 2009, will replace Nersesian as EMG president.
Microfluidics developer Rheonix has appointed Tom Karpen to be VP of operations and Terry Howell to be quality manager. Karpen has more than 20 years experience in technology businesses, including at GE Inspection Technologies. Howell has worked in biotechnology regulatory affairs and bioassay quality control for more than a decade, most recently at Percivia.
Two scientists at the Babraham Institute, Wolf Reik and Peter Fraser, have been elected as members of the Academia Europaea, an international association of scientists and scholars with elected members from the European research community. Reik is head of Babraham's Epigenetics Lab and a professor of epigenetics at the University of Cambridge. Fraser heads the institute's Laboratory of Nuclear Dynamics.
Sera Prognostics has appointed Gregory Critchfield to take over the company's CEO post, and Doug Fisher of InterWest Partners, Kim Kamdar of Domain Associates, and Joshua Phillips of Catalyst Ventures to join its board of directors. Critchfield, who currently is chairman of Sera's board, formerly was president of Myriad Genetic Laboratories. The company made the announcement this week in connection with a $19.3 million investment from InterWest Partners and Catalyst Health Ventures, among others.
Prometheus Laboratories has appointed Peter Heseltine to be senior VP and chief medical officer. Heseltine most recently was VP and medical director of Global Businesses at Beckman Coulter and he was medical director of Infectious Diseases at Nichols Institute Quest Diagnostics.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.